As shown in Table 4, 8 out of 14 MuSK-MG patients showed a good response to pyridostigmine bromide therapy, and this proportion was lower than that in AChR-MG group and DSN-MG group (P < 0.001, P < 0.001). This evidence concerns the gene DSTN and myasthenia gravis.